Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color
Status:
Completed
Trial end date:
2019-09-25
Target enrollment:
Participant gender:
Summary
This will be a single-center, randomized, double-blinded, vehicle-controlled clinical study
to determine the efficacy of Enstilar® foam, a combination of calcipotriene and betamethasone
dipropionate 0.005%/0.064%, in the treatment of psoriasis vulgaris in skin of color (FST
IV-VI). This study will also evaluate the degree of erythema versus hyperpigmentation in
psoriasis plaques in skin of color (and its change with Enstilar ® treatment) as well as the
effect of Enstilar ® on post-inflammatory hyperpigmentation and quality of life.